Clinical implications of research on the box-jellyfish Chironex fleckeri.
Despite several decades of laboratory research, many anecdotal clinical publications and successful production of antivenom, the active components of Chironex fleckeri venom and their mechanisms of toxicity remain poorly elucidated. Conflicting results of animal experiments and venom studies and the lack of controlled clinical trials necessitate caution in formulating protocols of clinical management. Of particular note are that in severe envenomation (1) clinical deterioration can occur within minutes and cardiac support must be emphasised in addition to respiratory support; (2) larger doses of antivenom may be appropriate; and (3) recommendations of therapy with verapamil and other cardioactive drugs remain controversial.
Currie
B
B
Menzies School of Health Research, Casuarina, Northern Territory, Australia.
D000818:Animals; D000997:Antivenins / Q000008:administration & dosage / Q000627:therapeutic use*; D001733:Bites and Stings / Q000628:therapy*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003064:Cnidarian Venoms / Q000378:metabolism* / Q000506:poisoning; D006801:Humans; D037401:Scyphozoa / Q000378:metabolism*; D014700:Verapamil / Q000627:therapeutic use
D000997:Antivenins; D002316:Cardiotonic Agents; D003064:Cnidarian Venoms; D014700:Verapamil